Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB)

Today's Latest Price: $3.79 USD

0.14 (-3.56%)

Updated Jul 7 6:55pm

Add PACB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

PACB Stock Summary

  • The price/operating cash flow metric for Pacific Biosciences Of California Inc is higher than 85.81% of stocks in our set with a positive cash flow.
  • PACB's price/sales ratio is 6.72; that's higher than the P/S ratio of 82.33% of US stocks.
  • With a year-over-year growth in debt of -29.14%, Pacific Biosciences Of California Inc's debt growth rate surpasses merely 10% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pacific Biosciences Of California Inc are JG, MRAM, KIN, NSTG, and SBBP.
  • Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to
PACB Daily Price Range
PACB 52-Week Price Range

PACB Stock Price Chart Technical Analysis Charts

PACB Price/Volume Stats

Current price $3.79 52-week high $6.13
Prev. close $3.93 52-week low $2.20
Day low $3.71 Volume 754,600
Day high $3.88 Avg. volume 2,060,061
50-day MA $3.58 Dividend yield N/A
200-day MA $4.23 Market Cap 584.84M

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Latest News Stream

Event/TimeNews Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.

Hedge Funds Are Selling Pacific Biosciences of California, Inc. (PACB)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 23, 2020

Pacific Bio files for $250M mixed shelf

Pacific Biosciences of California (PACB) has filed a prospectus for a $250M mixed shelf offering.Shares down 2% after hours....

Seeking Alpha | June 10, 2020

Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller

Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year. Dr. Hunkapiller plans to remain on the Board of Directors. The company also announced that Susan K. Barnes plans to retire and will be leaving the company in August 2020.

Yahoo | June 10, 2020

Pacific Biosciences of California, Inc. Announces Rescheduling of 2020 Annual Meeting of Stockholders and Move to Virtual Meeting

The Board of Directors of Pacific Biosciences of California, Inc. (PACB) (the “Company”) has announced that it is rescheduling the date of the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) previously scheduled for Thursday, June 18, 2020, to Tuesday, August 4, 2020, at 9:00 a.m., Pacific Time, and  changing  the format to a virtual meeting in light of the continuing public health impact of the COVID-19 pandemic. In connection with the change of the Annual Meeting date, the record date for determining stockholders entitled to attend and vote at the Annual Meeting has been changed to 5:00 p.m. Pacific Time on Monday, June 15, 2020. Furthermore, the Company will be revising its proposal to stockholders to approve the Company 2020 Equity Incentive Plan and would lik...

Yahoo | June 8, 2020

Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Investment Research | June 5, 2020

Read More 'PACB' Stories Here

PACB Price Returns

1-mo -2.82%
3-mo 30.69%
6-mo -19.87%
1-year -36.83%
3-year 10.17%
5-year -28.22%
YTD -26.26%
2019 -30.54%
2018 180.30%
2017 -30.53%
2016 -71.06%
2015 67.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8241 seconds.